Optimizing regional infusion treatment strategies for melanoma of the extremities

References

• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol.146 (Suppl. 61), 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society, GA, USA (2008).
   Google Scholar
• Miller AJ, Mihm MC Jr. Melanoma. N. Engl. J. Med.355(1), 51–65 (2006).
   PubMed Web of Science ®Google Scholar
• Balch CM, Houghton AN, Soper AJ, Soong S, Thompson JF. Isolated Limb Infusion. Quality Medical Publishing, MO, USA (2008).
   Google Scholar
• Koops HS, Vaglini M, Suciu S et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized Phase III trial: European Organization for Research and Treatment of Cancer Malignant Melanoma cooperative group protocol 18832, the World Health Organization Melanoma Program trial 15, and the North American Perfusion Group Southwest Oncology group-8593. J. Clin. Oncol.16(9), 2906–2912 (1998).
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Ross MI, Johnson MM et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann. Surg. Oncol.12(8), 587–596 (2005).
   PubMed Web of Science ®Google Scholar
• Kretschmer L, Beckmann I, Thoms KM, Mitteldorf C, Bertsch HP, Neumann C. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann. Surg. Oncol.13(8), 1105–1112 (2006).
   PubMed Web of Science ®Google Scholar
• Balch CM, Houghton AN, Sober A, Soong S. Recurrent Regional Metastases and Their Management. Quality Medical Publishing, MO, USA (1998).
   Google Scholar
• Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann. Surg.148(4), 616–632 (1958).
   PubMed Web of Science ®Google Scholar
• Ariyan CE, Brady MS. History of regional chemotherapy for cancer of the extremities. Int. J. Hyperthermia24(3), 185–192 (2008).
   PubMed Web of Science ®Google Scholar
• Creech O Jr, Krementz ET, Ryan RF, Reemtsma K, Winblad JN. Experiences with isolation-perfusion technics in the treatment of cancer. Ann. Surg.149(5), 627–640 (1959).
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Ciocatto EC, Giovanella BC et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer20(9), 1351–1381 (1967).
   PubMed Web of Science ®Google Scholar
• Stehlin JS Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg. Gynecol. Obstet.129(2), 305–308 (1969).
   PubMedGoogle Scholar
• Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann. Surg.245(4), 591–596 (2007).
   PubMed Web of Science ®Google Scholar
• Minor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer55(11), 2638–2644 (1985).
   PubMed Web of Science ®Google Scholar
• Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am. J. Surg.150(1), 32–35 (1985).
   PubMed Web of Science ®Google Scholar
• Kroon BB, Van Geel AN, Benckhuijsen C, Wieberdink J. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res.7(3 Pt B), 441–442 (1987).
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Calabro A, Giannarelli D et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer63(12), 2551–2561 (1989).
   PubMed Web of Science ®Google Scholar
• Kroon BB, Klaase JM, van Geel BN, Eggermont AM, Franklin HR, van Dongen JA. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur. J. Cancer29A(3), 325–328 (1993).
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, van Geel AN et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J. Am. Coll. Surg.178(6), 564–572 (1994).
   PubMed Web of Science ®Google Scholar
• Aloia TA, Grubbs E, Onaitis M et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch. Surg.140(11), 1115–1120 (2005).
   PubMedGoogle Scholar
• Cornett WR, McCall LM, Petersen RP et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J. Clin. Oncol.24(25), 4196–4201 (2006).
   PubMed Web of Science ®Google Scholar
• Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB. Isolated limb perfusion for unresectable melanoma of the extremities. Arch. Surg.139(11), 1237–1242 (2004).
   PubMedGoogle Scholar
• Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J. Surg.19(3), 363–368 (1995).
   PubMed Web of Science ®Google Scholar
• Beasley GM, Caudle A, Petersen RP et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J. Am. Coll. Surg.208(5), 706–715 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin. Surg. Oncol.14(3), 238–247 (1998).
   PubMed Web of Science ®Google Scholar
• Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol.10(1), 52–60 (1992).
   PubMed Web of Science ®Google Scholar
• Kroon HM, Lin DY, Kam PC, Thompson JF. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann. Surg. Oncol.16(5), 1193–1201 (2009).
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.20(2), 287–289 (1991).
   PubMed Web of Science ®Google Scholar
• van de Merwe SA, van den Berg AP, Kroon BB, van den Berge AW, Klaase JM, van der Zee J. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int. J. Hyperthermia9(2), 205–217 (1993).
   PubMed Web of Science ®Google Scholar
• Thompson JF, Morton DL, Kroon BB. Isolated Limb Perfusion for Melanoma: Technical Aspects. Martin Dunitz, London, UK (2004).
   Google Scholar
• Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann. Surg. Oncol.9(2), 127–136 (2002).
   PubMed Web of Science ®Google Scholar
• Parsons PG, Carter FB, Morrison L, Regius MS. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res.41(4), 1525–1534 (1981).
   PubMed Web of Science ®Google Scholar
• Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann. Surg. Oncol.15(11), 3003–3013 (2008).
   PubMed Web of Science ®Google Scholar
• Beasley GM, Petersen RP, Yoo J et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann. Surg. Oncol.15(8), 2195–2205 (2008).
   PubMed Web of Science ®Google Scholar
• Brady MS, Brown K, Patel A, Fisher C, Marx W. A Phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann. Surg. Oncol.13(8), 1123–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can. J. Surg.44(3), 189–192 (2001).
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Thompson JF, de Wilt JH, Doubrovsky A, de Faria Lima R, Kam PC. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur. J. Surg. Oncol.30(10), 1107–1112 (2004).
   PubMed Web of Science ®Google Scholar
• Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer115(9), 1932–1940 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch. Surg.132(8), 903–907 (1997).
   PubMed Web of Science ®Google Scholar
• Cheng TY, Grubbs E, Abdul-Wahab O et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am. J. Surg.186(5), 460–467 (2003).
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Hart GA, Eggermont AM et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J. Am. Coll. Surg.188(5), 522–530 (1999).
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin. Surg. Oncol.14(3), 224–231 (1998).
   PubMedGoogle Scholar
• McMahon N, Cheng TY, Beasley GM et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann. Surg. Oncol.16(4), 953–961 (2009).
   PubMed Web of Science ®Google Scholar
• Ko SH, Ueno T, Yoshimoto Y et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin. Cancer Res.12(1), 289–297 (2006).
   PubMed Web of Science ®Google Scholar
• Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am. J. Surg.188(5), 532–537 (2004).
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Abdel-Wahab O, Cheng TY et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J. Am. Coll. Surg.199(3), 419–427 (2004).
   PubMed Web of Science ®Google Scholar
• Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol.30(6), 445–600 (1995).
   PubMed Web of Science ®Google Scholar
• Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res.44(11), 5427–5431 (1984).
   PubMed Web of Science ®Google Scholar
• Suzukake K, Petro BJ, Vistica DT. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem. Pharmacol.31(1), 121–124 (1982).
   PubMed Web of Science ®Google Scholar
• Robson CN, Lewis AD, Wolf CR et al. Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity. Cancer Res.47(22), 6022–6027 (1987).
   PubMed Web of Science ®Google Scholar
• Suzukake K, Vistica BP, Vistica DT. Dechlorination of l-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol.32(1), 165–167 (1983).
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Ueno T, Abdel-Wahab O et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery136(2), 210–218 (2004).
   PubMed Web of Science ®Google Scholar
• Ueno T, Ko SH, Grubbs E et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol. Cancer Ther.5(3), 732–738 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshimoto Y, Augustine CK, Yoo JS et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol. Cancer Ther.6(5), 1492–1500 (2007).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature362(6423), 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57(20), 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med.7(9), 987–989 (2001).
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res.13(13), 3942–3950 (2007).
   PubMed Web of Science ®Google Scholar
• Augustine CK, Yoshimoto Y, Gupta M et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res.68(10), 3777–3784 (2008).
   PubMed Web of Science ®Google Scholar
• Beasley GM, McMahon N, Sanders G et al. A Phase I study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer115(20), 4766–4774 (2009).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Niu G, Bowman T, Huang M et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene21(46), 7001–7010 (2002).
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene21(13), 2000–2008 (2002).
   PubMed Web of Science ®Google Scholar
• Augustine CK, Yoo JS, Potti A et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin. Cancer Res.15(2), 502–510 (2009).
   PubMed Web of Science ®Google Scholar